The track category is the heading under which your abstract will be reviewed and later published in the conference printed matters if accepted. During the submission process, you will be asked to select one track category for your abstract.
HIV/AIDS has emerged as the single most formidable challenge to public health, human rights, and development in the new millennium. The epidemic of HIV/AIDS is now progressing at a rapid pace among young people. Many adolescents around the world are sexually active and because many sexual contacts among them are unprotected, they are at a risk of contracting sexually transmitted diseases (STDs) including HIV/AIDS.
- Track 1-1Safer sex
- Track 1-2HIV Prevention and Education
- Track 1-3Promote HIV Testing
- Track 1-4HIV Events
Sexually transmitted diseases (STDs) are infections that are passed from one person to another through sexual contact. The causes of STDs are bacteria, parasites, yeast, and viruses. Most STDs affect both men and women, but in many cases the health problems they cause can be more severe for women. If a pregnant woman has an STD, it can cause serious health problems for the baby. Types of Sexually transmitted diseases Chlamydia, Genital herpes, Gonorrhea, HIV/AIDS, HPV, Syphilis, Trichomoniasis
- Track 2-1Chlamydia
- Track 2-2Gonorrhea
- Track 2-3Genital Herpes
- Track 2-4Human Papillomavirus (HPV)
- Track 2-5Syphilis
- Track 2-6Bacterial Vaginosis
- Track 2-7Trichomoniasis
- Track 2-8Viral Hepatitis
Bacterial STDs are curable through treatment with antibiotics. Curable, that is, as long as you see a health-care provider, get tested and treated, follow through on all the medication, avoid sexual contact until cured, and make sure your sexual partner(s) get tested and treatment as well. Like viral STDs, bacterial STDs/STIs often give no warning signs or symptoms. This means you can get infected and infect a sexual partner without knowing it and serious complications which can cause irreversible damage can progress silently before you ever recognize a problem.
HIV symptoms that are more common amongst women than men. The early symptoms of HIV are sometimes very mild and can be easily dismissed as cold and flu symptoms. Early HIV symptoms include swollen glands, rashes, infections, and low grade fevers. A latency period of up to ten years where few (if any) symptoms are experienced. Swollen or painful glands are likely to be the main indication of an HIV infection during this time. Constitutional symptoms such as fatigue, weight-loss and dementia can signify a HIV infection is advancing into its later stages.
- Track 4-1Early symptoms and prevention
- Track 4-2Menopause and HIV
- Track 4-3Contraception and HIV
- Track 4-4Safe conception for serodiscordant couples
HIV can be transmitted from an HIV-positive woman to her child during pregnancy, childbirth and breastfeeding. Mother-to-child transmission (MTCT) accounts for over 90% of new HIV infections among children. Prevention of mother-to-child transmission (PMTCT) programmes provide antiretroviral treatment to HIV-positive pregnant women to stop their infants from acquiring the virus. Pregnant women with HIV receive HIV medicines to reduce the risk of mother-to-child transmission of HIV and to protect their own health. HIV medicines are recommended for everyone infected with HIV. HIV medicines help people with HIV live longer, healthier lives and reduce the risk of transmission of HIV.
- Track 5-1Reducing pre-partum and intra-partum transmission to infants
- Track 5-2Reducing post-partum transmission in infants
- Track 5-3Promoting health and reducing maternal mortality in HIV-positive women
The identification of viral and cellular drug targets is essential for fueling the drug development pipeline. Early drug discovery efforts concentrated on a relatively small number of viral targets such as HIV reverse transcriptase (an enzyme that catalyzes the synthesis of viral DNA within infected cells from the RNA template carried by infectious virions) and HIV protease (an enzyme that cleaves and processes viral precursor proteins allowing virion maturation). Treatment regimens containing combinations of reverse transcriptase and protease inhibitors, commonly known as highly active antiretroviral therapy, or HAART, revolutionized the treatment of people with HIV by markedly lowering viral load and decreasing the incidence of AIDS-associated opportunistic infections
- Track 7-1HIV controllers and long term non-progressors
- Track 7-2Highly exposed seronegative individuals
- Track 7-3Correlates of immune protection
Sexual stigma is a form of social stigma against people who are perceived to be non-heterosexual because of their beliefs, identities or behaviors. Privileged individuals, or the majority group members, are the main contributors of placing sexual stigmas on individuals and their minority group.It is those who hold a higher status that determine within a society which groups are deemed unworthy of a higher status by labeling their specific actions or beliefs. Stereotypes are then produced which further the debilitating effects of the label(s) placed on group members with non-heterosexual beliefs or practices
Immunizations are an important part of your HIV care plan because they can help protect you from serious illness. Vaccination recommendations are determined by weighing the benefits of vaccination against the risks. Although vaccination recommendations for HIV-infected patients are similar to those for HIV-uninfected patients in many respects, HIV can alter the efficacy and safety of vaccines and affect the susceptibility of the patient to the diseases for which immunization can confer protection. Thus, HIV infection impacts both the risks and the benefits of specific vaccinations.
- Track 9-1Adjuvants
- Track 9-2Therapeutic vaccines
- Track 9-3Cell-based preventative vaccines
- Track 10-1Innate immunity
- Track 10-2Humoural immunity
- Track 10-3Mucosal immunity
- Track 10-4Cellular immunity
Sexually transmitted Infections (STIs) rank among the most important health issues for the people especially the young adults worldwide. Young people tend to engage in sexual activity at younger ages in the past decade than in the 1970s, and 1980s. Knowledge is an essential precursor of sexual risk reduction. A cross-sectional study was conducted in Pulau Pinang, Malaysia, to produce the baseline information about school students' awareness and perception about sexually transmitted Infections (STIs) and their sexual activity to help establish control and education programmes.
People who were diagnosed with HIV/AIDS could expect to live only 1-2 years after that diagnosis. This meant that the issues of aging were not a major focus for people with HIV disease. People with HIV who are diagnosed early in their infection, and who get and stay on ART can keep the virus suppressed and live as long as their HIV-negative peers
The human papillomavirus vaccine is one example of a new biomedical technology for sexual health promotion. Additional appearing technologies include other STD vaccines, microbicides and pre-exposure prophylaxis for HIV prevention Each of these technologies has its own limits with respect to effective utilization. Microbicides are materials (creams, gels or foams) that are inserted into vagina or rectum for the prevention of HIV or other STDs. PrEP, another emerging biomedical elucidation, involves the use of antiretroviral medications for HIV prevention.
Current Research in Virology and Retrovirology provides a platform for innovative research, new concepts, and novel developments in the field of Virology and Retrovirology to solve the related issues in that particular field.
Most people who have become recently infected with HIV will not have any symptoms. They may, however, have a flu-like illness within a month or two after exposure to the virus, with fever, headache, tiredness, and enlarged lymph nodes (glands of the immune system easily felt in the neck and groin). These symptoms usually disappear within a week to a month and are often mistaken for those of other viral infections. During this period, people are very infectious, and HIV is present in large quantities in blood, semen, and vaginal fluids.
- Track 18-1Preclinical drug development
- Track 18-2Nucleic acid-based HIV therapies
- Track 18-3Prophylactic drug and microbicide development
- Track 19-1Mucosal transmission
- Track 19-2Vertical transmission
- Track 19-3Blood borne transmission
- Track 19-4Acute and early infection